

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1-25. (Cancelled)

26. (Currently amended) ~~The A dermatological formulation according to claim 1, wherein said plant extract having extracellular protease inhibiting activity comprising a physiologically acceptable carrier and an effective amount of one or more plant extracts that inhibit the activity of at least one extracellular protease selected from the group of: matrix metalloprotease-1 (MMP-1), matrix metalloprotease-2 (MMP-2), matrix metalloprotease-3 (MMP-3), matrix metalloprotease-9 (MMP-9) and human leukocyte elastase (HLE), wherein said one or more plant extracts modulates one or more cellular activities in skin cells, each of said one or more plant extracts is derived by solvent extraction from a plant selected from the group of: *Beta vulgaris* L., *Brassica oleracea* L., *Capsicum annuum* L., *Chenopodium quinoa*, *Daucus carota* L., *Geranium x cantabrigiense*, *Juniperus communis* L., *Melilotus alba* Medik., *Pastinaca sativa* L., *Potentilla anserina* L., *Rhus typhina* L., *Solanum melongena* L., *Tropaeolum majus* L., *Vaccinium angustifolium*, x *Triticosecale* spp. and/or *Zea mays* L.~~

27 – 29. (Cancelled)

30. (New) The dermatological formulation according to claim 26, wherein said one or more cellular activities in skin cells are selected from the group of: attenuating endothelial cell migration; increasing collagen production; inhibiting UV-induced extracellular protease activity and inhibiting dermal contraction.

31. (New) The dermatological formulation according to claim 26, wherein said solvent is an aqueous solvent, an alcoholic solvent, or a combination thereof.

32. (New) The dermatological formulation according to claim 31, wherein said alcoholic solvent is ethanol or a glycol.
33. (New) The dermatological formulation according to claim 32, wherein said glycol is butylene glycol or propylene glycol.
34. (New) The dermatological formulation according to claim 26, wherein at least one of said plant extracts is derived from *Capsicum annuum* L.
35. (New) The dermatological formulation according to claim 26, wherein at least one of said plant extracts is derived from *Chenopodium quinoa*.
36. (New) The dermatological formulation according to claim 26, wherein at least one of said plant extracts is derived from *Geranium x cantabrigiense*.
37. (New) The dermatological formulation according to claim 26, wherein at least one of said plant extracts is derived from *Juniperus communis* L.
38. (New) The dermatological formulation according to claim 26, wherein at least one of said plant extracts is derived from *Melilotus alba* Medik.
39. (New) The dermatological formulation according to claim 26, wherein at least one of said plant extracts is derived from *Pastinaca sativa* L.
40. (New) The dermatological formulation according to claim 26, wherein at least one of said plant extracts is derived from *Potentilla anserina* L.
41. (New) The dermatological formulation according to claim 26, wherein at least one of said plant extracts is derived from *Rhus typhina* L.
42. (New) The dermatological formulation according to claim 26, wherein at least one of said plant extracts is derived from *Tropaeolum majus* L.

43. (New) The dermatological formulation according to claim 26, wherein at least one of said plant extracts is derived from *x Triticosecale spp.*
44. (New) The dermatological formulation according to claim 26, wherein at least one of said plant extracts is derived from *Zea mays L.*
45. (New) The dermatological formulation according to claim 26, further comprising a moisturising agent.
46. (New) The dermatological formulation according to claim 26, wherein said formulation is formulated for topical or oral administration.
47. (New) A method for maintaining and/or improving the health and/or appearance of the skin in a subject comprising administering the dermatological formulation according to claim 26 to said subject.
48. (New) A method for attenuating or preventing skin ageing in a subject comprising administering the dermatological formulation according to claim 26 to said subject.
49. (New) A method for treating or preventing a dermatological condition in a subject comprising administering the dermatological formulation according to claim 26 to said subject.
50. (New) The method according to claim 49, wherein said dermatological condition comprises skin wrinkling, loss of skin elasticity, redness, and/or inflammation.
51. (New) The method according to claim 47, wherein said dermatological formulation is administered orally or topically.
52. (New) The method according to claim 48, wherein said dermatological formulation is administered orally or topically.

53. (New) The method according to claim 49, wherein said dermatological formulation is administered orally or topically.